We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Medica 2024 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Randox and Bosch Healthcare Alliance Targets COVID-19 Testing

By LabMedica International staff writers
Posted on 28 Oct 2020
A partnership between Randox Laboratories (Crumlin, UK) and Bosch Healthcare (Waiblingen, Germany) aims to alter the testing landscape in both laboratory and non-laboratory settings toward the rapid detection of COVID-19.

The collaborative approach of Randox and Bosch Healthcare focuses on safety precautions as well as solutions to both analyzing and differentiating COVID-19 from other viral respiratory diseases. Their combined efforts have resulted in the launch of the Vivalytic, an all-in-one solution for molecular diagnostics, consolidating nucleic acid extraction, polymerase chain reaction (PCR) and detection on a single platform.

Image: Randox and Bosch Healthcare Collaboratively Combat COVID-19 with Game-Changing Partnership (Photo courtesy of Randox Laboratories)
Image: Randox and Bosch Healthcare Collaboratively Combat COVID-19 with Game-Changing Partnership (Photo courtesy of Randox Laboratories)

The Viral Respiratory Infection array (VRI) rapidly detects the SARS-CoV-2 virus that causes COVID-19 while simultaneously differentiating between nine other respiratory diseases, in less than two and a half hours. Randox, Bosch Healthcare and R-Biopharm also offer various analysis strategies to detect SARS-CoV-2. Capable of providing reliable results in just 39 minutes, with a sensitivity of 98% and specificity of 100%, the Vivalytic SARS-CoV-2 rapid test is currently among the fastest PCR tests worldwide.

Randox and Bosch Healthcare offer a range of testing strategies, including the upcoming SARS-CoV-2 Pooling test. The SARS-CoV-2 Pooling test is a rapid solution for the detection of SARS-CoV-2, offering an accelerated decentralized testing approach for effectively and efficiently monitoring and detecting viral infection from the onset. The solution is capable of detecting SARS-CoV-2 from up to five pooled samples simultaneously with a capacity for processing more than 160 patient samples a day. Sample pooling allows more people to be tested quickly using fewer testing resources. The pooling can be done at the level of a ward, medical specialty, social bubble, or a group of colleagues. It also has potential for use in other settings, such as pre-operative screening, schools & universities, prisons, nursing homes, primary care, and large workplaces.

New
Gold Member
C-Reactive Protein Reagent
CRP Ultra Wide Range Reagent Kit
Antipsychotic TDM AssaysSaladax Antipsychotic Assays
New
Hepatitis B Virus Test
HBs Ab – ELISA
New
Toxoplasma Gondii Test
Toxo IgG ELISA Kit

Latest Industry News

Bio-Techne and ALZpath Partner to Advance Neurodegenerative Disease Research and Treatment

Microbiologics Acquires Diagnostic Quality Controls Manufacturer SensID

Beckman Coulter Partners with BioPorto for Global Distribution of Acute Kidney Injury NGAL Tests